Home
News
Create
Screeners
Insights
Anlon Healthcare
120.
13
+2.09
(+1.77%)
Market Cap
₹638.51 Cr
PE Ratio
18.22
Industry
Healthcare
Buy
Sell
Company Performance:
1D
+1.77%
1M
-10.34%
6M
+30.96%
1Y
+30.96%
5Y
+30.96%
View Company Insights
Latest news about Anlon Healthcare
Anlon Healthcare Releases Q3 FY26 Investor Presentation with Strong Growth Metrics
8 days ago
Anlon Healthcare Limited published its comprehensive investor presentation for Q3 and 9M FY26, demonstrating remarkable financial performance with Q3 revenue growth of 280% to ₹35.58 crores and EBITDA margin expansion to 35.06%. The company achieved a positive turnaround with ₹5.15 crores PAT in Q3 FY26 compared to a loss in the previous year, while outlining strategic growth plans targeting 30% revenue CAGR over the next three years.
Anlon Healthcare Submits Q3FY26 Monitoring Report with ₹9,579.04 Lakh IPO Fund Utilization
Feb 09, 2026
Anlon Healthcare Limited Announces New Product Development and Trade Agreement Impact
Jan 28, 2026
Neomile Asset Managers Reduces Stake in Anlon Healthcare to 5.16% Through Open Market Sale
Jan 09, 2026
Neomile Asset Managers Reduces Stake in Anlon Healthcare Through Open Market Sale
Jan 09, 2026
More news about Anlon Healthcare
09
Jan 26
Anlon Healthcare Completes Acquisition of 67.48% Stake in Apiqo Organics
Anlon Healthcare Limited completed its acquisition of 67.48% equity stake in Apiqo Organics Private Limited on January 9, 2026, making it a subsidiary. The transaction was executed under the Share Purchase Agreement dated December 2, 2025, and complies with Section 179(3)(e) & (j) of the Companies Act, 2013. The acquisition was disclosed under SEBI Listing Regulations with detailed information previously provided in December 2025 disclosure.
19
Dec 25
Anlon Healthcare Limited Plans New Marketing Office in Ahmedabad
Anlon Healthcare Limited has announced plans to establish a new marketing office in Ahmedabad, Gujarat, as part of its expansion strategy. The company made this disclosure through a regulatory filing under SEBI regulations. While specific timelines were not provided, the new office is expected to open in the near future, strengthening Anlon's market presence in the Gujarat region.
18
Dec 25
Anlon Healthcare Q1FY26 Results Show Mixed Performance
Anlon Healthcare Limited released Q1FY26 results, showing a 12% YoY revenue decline to ₹3,329.72 lacs. Net profit decreased by 5.8% to ₹354.69 lacs. Despite revenue challenges, the company demonstrated effective cost management with total expenses down 12.6%. Notably, earnings per share significantly improved to ₹2.22 from ₹0.41 in Q1FY25, a 441.5% increase. The balance sheet strengthened with total assets rising to ₹19,775.76 lacs and total equity increasing to ₹8,396.86 lacs.
08
Dec 25
Anlon Healthcare Shareholders Approve Strategic IPO Fund Reallocation for Acquisitions
Anlon Healthcare Limited successfully secured overwhelming shareholder approval for reallocating ₹2,332.69 lakhs from IPO capital expenditure funds towards strategic acquisitions. The postal ballot voting concluded on January 7, 2026, with 99.99% of votes cast in favor of the resolution, enabling the company to proceed with planned acquisitions of Bizotic Lifescience and Apiqo Organics for inorganic growth.
02
Dec 25
Anlon Healthcare Acquires Majority Stake in Apiqo Organics for Rs 5.40 Crore
Anlon Healthcare Limited has entered into a Share Purchase Agreement to acquire a 67.48% stake in Apiqo Organics Private Limited for Rs 5.40 crore. The acquisition involves 55,33,500 equity shares at Rs 9.76 per share. This strategic move aims to enhance Anlon's vertical integration, add 700-800 MT of annual manufacturing capacity for advanced pharmaceutical intermediates, secure critical supply, and strengthen its market position. Apiqo Organics, formerly M/s Apple Life Science, manufactures pharmaceutical intermediates and chemicals. The transaction is expected to close within three months, subject to conditions.
19
Nov 25
Anlon Healthcare Showcases Global Reach and Growth in Q2/H1 FY26 Investor Presentation
Anlon Healthcare, a Gujarat-based pharmaceutical intermediates and APIs manufacturer, has released its Q2/H1 FY26 investor presentation. The company reported significant growth, with Q2 FY26 total income increasing by 115.74% to INR 52.23 Cr and PAT rising by 259.85% to INR 9.32 Cr year-on-year. Operating at 84.41% capacity utilization, Anlon has filed 21 DMFs globally. The company's balance sheet shows a net worth of INR 214.32 Cr and reduced long-term borrowings. Strategic initiatives include targeting 10-15 global DMF filings in 5 years, entering the Industrial and Fine chemicals business, and strengthening its leadership team with new appointments.
11
Nov 25
Anlon Healthcare Reports Strong Q2 FY26 Results, Plans Capacity Expansion
Anlon Healthcare Limited has reported strong financial results for Q2 FY26. Total income rose 116% to INR 52.32 crore, while profit after tax increased nearly 4 times to INR 9.32 crore. Revenue from operations grew 37.8% to INR 33.29 crore. For the half-year, revenue reached INR 61.99 crore with a profit after tax of INR 12.86 crore. The company's total assets increased to INR 287.52 crore. Anlon Healthcare is planning a 700 metric ton greenfield expansion and exploring inorganic acquisitions, aiming for a 30% revenue CAGR over the next three years.
06
Nov 25
Neomile Asset Managers Reduces Stake in Anlon Healthcare Through Open Market Sale
Neomile Asset Managers Private Limited has significantly reduced its stake in Anlon Healthcare Limited through open market transactions between November 3-4, 2025. The firm sold 14,75,992 shares, decreasing its holding from 10.40% to 7.62% of the total share capital, a reduction of 2.78%. Neomile Growth Fund-Series I acted in concert with Neomile Corporate Advisory Limited for this transaction. Anlon Healthcare remains listed on both the National Stock Exchange and Bombay Stock Exchange.
20
Sept 25
Anlon Healthcare Unveils Two New Anti-Malarial Products for November 2025 Launch
Anlon Healthcare Limited has successfully developed two new anti-malarial products, Artemether and Lumefantrine. The company plans to launch these medications in November 2025, marking a significant expansion of its product portfolio. This development aligns with Anlon Healthcare's strategy to diversify its offerings and address global health concerns. The announcement was made in compliance with SEBI regulations, with further updates expected as the launch date approaches.
15
Sept 25
Anlon Healthcare Limited Reports Shareholding Change Following Equity Share Acquisition
Anlon Healthcare Limited has disclosed a substantial change in its shareholding structure following an acquisition of equity shares. The company has notified both BSE and NSE about this change, complying with SEBI regulations. The disclosure was made on September 13, as per LODR data, and was signed by Managing Director Punitkumar Rasadia. While specific details of the shareholding change were not provided, such disclosures typically indicate a substantial acquisition or change in company ownership.
Anlon Healthcare
120.
13
+
2.
09
(+
1.
77
%)
1 Year Returns:
+30.96%
Industry Peers
Sun Pharmaceutical
1,724.40
(+
0.
64
%)
Divis Laboratories
6,291.00
(-
0.
10
%)
Torrent Pharmaceuticals
4,241.70
(+
0.
36
%)
Cipla
1,341.10
(+
0.
92
%)
Dr Reddys Laboratories
1,280.40
(-
0.
15
%)
Lupin
2,219.40
(-
0.
42
%)
Zydus Life Science
900.75
(-
0.
18
%)
Mankind Pharma
2,024.30
(-
0.
75
%)
Aurobindo Pharma
1,158.80
(-
1.
08
%)
Alkem Laboratories
5,392.00
(+
0.
28
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation